Merck To Get Chronic Cough P2X3 Inhibitor Candidate With Afferent Buy

A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.